Anal Fissure Clinical Trial
Official title:
An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing
Verified date | January 2015 |
Source | RDD Pharma Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ministry of Health |
Study type | Interventional |
This is an open label study. The study will consist of 2 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2). Approximately 30 subjects will participate into this 8-week study. The primary objective is to examine the dose effect of coated Nifedipine suppository on Anal fissure pain and healing.
Status | Terminated |
Enrollment | 33 |
Est. completion date | November 2015 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Single anal fissure - Signed written informed consent; - Male or female subjects 18 to 65 years of age; - Has chronic anal fissure defined as history of anal pain at least three days a week for 30 days duration or more - Visible fibers of the internal sphincter were seen at the base of the fissure or if a sentinel pile was present. - VAS of > 35 mm in screening visit - If female, is non-lactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to entry to the study or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice or be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration. Exclusion Criteria: - Known allergy to Nifedipine, polyethylene-glycol, propylene Glycol or silicone. - Fissure resulting from inflammatory bowel disease, venereal disease, perianal psoriasis, immunodeficiency syndrome. - Anal abscess - Fixed anal stenosis - Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, moderate to severe congestive heart failure, or cardiac valve abnormalities; - Type 1 diabetes mellitus; - Insulin treated type 2 diabetes mellitus; - History of Renal insufficiency. - History of Liver insufficiency. - Malignant disease within 5 years of screening; - Has uncontrolled hypertension (sitting blood pressure <160/95 mmHg at screening) - History of chronic gastrointestinal disease. - History of rectal surgery. - History of gastrointestinal surgery. - History of HIV, hepatitis B, hepatitis C. - In need of chronic use of medication, with the exception of birth control medications. - Currently uses medication for acute illness (other than medications for use of treatment/pain relief of anal fissure). - Has used, in the last two weeks, drugs that may affect blood coagulation, such as Aspirin at a dose higher than 500 mg/day , Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine. - Is using drug that may affect rectal tone: - Calcium Channel Blocker such as: - Nifedipine (Osmo-Adlat, Pressolat, Nifedipine -Teva, Nifedilong) - Amlodipine (Amlow, Norvasc, Amlodipine-Teva) - Lercadipine (Vasodip) - Verapamil (Ikacor, Ikapress, Verapress) - Felodipine (Penedil) - Diltiazem (Adizem, Dilatam) - Nitrate donors such as: - Glyceryl Trinitrate (Deponit) - Isosorbid dinitrate (Isoket, Isolong) - Isosrbid mononitrate (Monocord, Monolong, Mononit) - Nitroglycerine (Nitrocine, Nitroderm, Nitrolingual) - Has upon physical examination a rectal deformation or signs of rectal disease such as bleeding hemorrhoids, fistula. infection or space occupying lesion. - Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or - Is employed by RDD Pharma Ltd. |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Israel | Macabi outpatient clinic | Beer Sheba | Negev |
Israel | Macabi outpatient clinic | Rehovot | |
Israel | Macabi HMO outpatient clinic | Tel Aviv | |
Israel | Asaf Harofe Hospital | Zrifin |
Lead Sponsor | Collaborator |
---|---|
RDD Pharma Ltd |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To examine the effect of coated Nifedipine suppository on Anal fissure pain as measured by Visual Analog Score | 8 weeks after study initiation | No | |
Secondary | To investigate the Safety and tolerability of coated Nifedipine suppositories in Anal Fissure patients . | safety will be assessed by the number of participants with adverse events. Tolerability will be assessed by the number of participants that discontinue treatment. | 8 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Not yet recruiting |
NCT05405634 -
Microbiota in Chronic Anal Fissure and Its Association With Prognosis
|
||
Completed |
NCT05736926 -
Anal Fissure Among Survivors of COVID-19 Virus Infection.
|
||
Enrolling by invitation |
NCT00980369 -
The Importance of Lateral Internal Sphincterotomy Incision: Parallel or Vertical
|
N/A | |
Completed |
NCT05616455 -
Efficacy and Safety of Propionibacterium Extract Gel Versus 0.4% Glyceryl Trinitrate Ointment in the Treatment of Chronic Anal Fissure: a Randomised Controlled Trial
|
Phase 4 | |
Completed |
NCT04173130 -
Monocentric Feasibility Study for a New Medical Device for the Treatment of Anal Fissure With Botulinum Toxin
|
N/A | |
Completed |
NCT03345511 -
Ultrasound Guided Caudal Block for Benign Anal Surgery
|
N/A | |
Completed |
NCT05341180 -
Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: PEGASIS Trial
|
Phase 2/Phase 3 | |
Completed |
NCT03528772 -
Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure
|
N/A | |
Active, not recruiting |
NCT04428697 -
Sungurtekin Technique vs. Closed Lateral Internal Sphincterotomy Technique
|
N/A | |
Withdrawn |
NCT01920074 -
Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure
|
Phase 4 | |
Recruiting |
NCT01039051 -
Diet and Lifestyle Intervention Study in Postpartum Women in China
|
Phase 2/Phase 3 | |
Completed |
NCT00210444 -
Efficacy Study of Dysport® in the Treatment of Anal Fissure.
|
Phase 2 | |
Completed |
NCT00827736 -
Comparison of Treatment Success of Botox Injection in the Internal Sphincter Versus Isosorbidedinitrate Ointment in Patients With an Anal Fissure
|
Phase 4 | |
Withdrawn |
NCT02667535 -
PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure
|
Phase 1 | |
Not yet recruiting |
NCT06049524 -
Could Preoperative Assessment of Physical and Psychological Status Help Predict Pain After Anorectal Surgery?
|
||
Not yet recruiting |
NCT05709717 -
Regenerative Therapy With Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cells and Platelet-rich Plasma to Treat Complex Perianal Diseases
|
||
Completed |
NCT05038605 -
Topical vs Oral Metronidazole After Benign Anorectal Surgery
|
N/A | |
Not yet recruiting |
NCT03780998 -
Effects of Sodium Pentaborat Based Gel on Perianal Benign Diseases
|
||
Completed |
NCT03426449 -
Posterolateral Versus Lateral Internal Anal Sphincterotomy for Chronic Anal Fissure
|
N/A |